106
Participants
Start Date
April 6, 2017
Primary Completion Date
August 22, 2019
Study Completion Date
August 22, 2019
Saroglitazar magnesium 1 mg
Patients randomly assigned to this group will receive Saroglitazar magnesium 1 mg tablet orally once daily for 16 weeks.
Saroglitazar magnesium 2 mg
Patients randomly assigned to this group will receive Saroglitazar magnesium 2 mg tablet orally once daily for 16 weeks.
Saroglitazar magnesium 4 mg
Patients randomly assigned to this group will receive Saroglitazar magnesium 4 mg tablet orally once daily for 16 weeks.
Placebos
Patients randomly assigned to this group will receive placebo tablet orally once daily for 16 weeks.
Einstein Medical Center, Philadelphia
Mercy Medical Center, Baltimore
University of Florida, Gainesville
Avail Clinical Research, Orange City
Schiff Center for Liver Diseases/University of Miami, Miami
AIG Research, Hermitage
Gastro One, Germantown
Awasty Research Network, LLC, Marion
Indiana University, Indianapolis
Liver Consultants, Dallas
The Liver Institute, San Antonio
Swedish Medical Center, Seattle
Cedars-Sinai Medical Center, Los Angeles
California liver research institute, Pasadena
Catalina Research Institute, Montclair
Precision Research, Chula Vista
Precision Research, San Diego
University of Michigan, Ann Arbor
Zydus Therapeutics Inc.
INDUSTRY